tiprankstipranks
Trending News
More News >

Medpace Holdings Approves Key Proposals at Annual Meeting

Story Highlights
  • Medpace Holdings approved the Amended 2016 Plan, extending its expiration to 2035.
  • Key proposals, including director elections and executive compensation, were approved at the 2025 Annual Meeting.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Confident Investing Starts Here:

The latest update is out from Medpace Holdings ( (MEDP) ).

On May 16, 2025, Medpace Holdings, Inc. held its 2025 Annual Meeting of Stockholders, where several key proposals were approved. The stockholders approved the 2016 Amended and Restated Incentive Award Plan, which extended the expiration date to February 6, 2035, without increasing the number of shares for issuance. Additionally, the election of Class III Directors, the ratification of Deloitte & Touche LLP as the independent registered public accounting firm, and the advisory vote on executive compensation were all approved. A non-binding advisory stockholder proposal regarding simple majority voting was also passed.

The most recent analyst rating on (MEDP) stock is a Hold with a $345.00 price target. To see the full list of analyst forecasts on Medpace Holdings stock, see the MEDP Stock Forecast page.

Spark’s Take on MEDP Stock

According to Spark, TipRanks’ AI Analyst, MEDP is a Neutral.

Medpace Holdings demonstrates strong financial performance with robust revenue and profit growth, supported by positive cash flow metrics. However, technical analysis indicators suggest a bearish trend, and valuation metrics show the stock is fairly valued, providing no additional upside from a dividend perspective. The recent earnings call highlighted challenges, including declining business awards and EBITDA margin, which temper growth expectations. Overall, the stock is positioned moderately well with notable strengths but faces near-term uncertainties.

To see Spark’s full report on MEDP stock, click here.

More about Medpace Holdings

Medpace Holdings, Inc. operates in the clinical research industry, providing comprehensive services for the development of drugs and medical devices. The company focuses on supporting pharmaceutical, biotechnology, and medical device companies in their clinical trials and regulatory processes.

Average Trading Volume: 512,527

Technical Sentiment Signal: Hold

Current Market Cap: $8.38B

See more insights into MEDP stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App